Radioimmunotherapy in Solid Tumors (PNRR-MCNT2-2023-12378239-Aim2)

Recruiting now · Not applicable

Conditions studied: Glioblastoma

In brief

This is a prospective multicenter study of hypofractionated radiotherapy for the radiation treatment (RT) of solid tumors and in particular for Glioblastoma (in Aim 2). It is based on the results of ongoing studies at our Institute to validate the efficacy of extremely hypofractionated RT in neoadjuvant settings, which observed immunostimulatory effects of RT and the synergy with immune components. The collaboration between San Raffaele Hospital (Milan), the IRCCS Istituto Nazionale dei Tumori Fondazione G. Pascale (Naples) and the San Giuseppe Moscati Hospital of National Relief and High Specialty (Avellino) will ensure that patient recruitment, treatment and monitoring can be translated into facilities of the National Health System using common procedures. The various departments involved will treat patients with the same methods synergistically exploring the immuno/biological factors related to efficacy (and/or toxicity), based on new radioimmunotherapeutic approaches. Clinical and research activity will be developed jointly, drawing on the expertise in radiotherapy, radiomics, oncology, imaging and immunotherapy skills already available.

Key facts

Study ID

NCT06551909

Run by

IRCCS San Raffaele

People needed

30

Starts

2024-08-31

Expected to finish

2027-02-28

Last updated by the study team

2025-06-08

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Diagnosis of Glioblastoma.
• ECOG performance score 0-2 (defined during the first visit)
• Surgically removable lesion (according to the operability criteria established by the Neurosurgery Unit)
• For healthy volunteers, people who are as comparable as possible with the patient population in terms of sex and age will be recruited

You may not qualify if…

• Previous stroke
• Presence of another primary and/or metastatic tumor For healthy volunteers also, absence of primary and/or metastatic tumor

Where it is running

• IRCCS San Raffaele Scientific Institute — Milan, MI, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.